| Literature DB >> 26401857 |
David Chalmers1, Antonio Cusano2, Peter Haddock2, Ilene Staff2, Joseph Wagner2.
Abstract
PURPOSE: To assess whether retinal and central nervous system (CNS) comorbidities are risk factors for complications following robotic assisted laparoscopic prostatectomy (RALP).Entities:
Mesh:
Year: 2015 PMID: 26401857 PMCID: PMC4756993 DOI: 10.1590/S1677-5538.IBJU.2014.0464
Source DB: PubMed Journal: Int Braz J Urol ISSN: 1677-5538 Impact factor: 1.541
Patient demographics and clinical data of patients who underwent RALP.
| All patients | Control Group | Study Group | p (control vs. study group) | |||
|---|---|---|---|---|---|---|
| Number of patients (n) | 1868 | 1828 | 40 | - | ||
| Age (mean) (years) | 59.7±6.7 | 59.7±6.6 | 62.1±7.1 | 0.024 | ||
| BMI (mean) (kg/m2) | 28.2±4.5 | 28.2±4.6 | 28.2±3.6 | 0.992 | ||
| Total operative time (min) (mean, median, IQR) (min) | 180.9±44.9 | 180.9±44.9 | 181.3±46.2 | 0.963 | ||
| Robotic surgical time (min) (mean, median, range) (min) | 142.3±40.2 | 142.3±40.2 | 143.7±43.2 | 0.827 | ||
| Initial PSA (Median, IQR) (ng/mL) | 5.3±4.2 (3.5-6.5) | 4.8 (3.5-6.5) | 4.3 (3.0-5.6) | 0.039 | ||
| D'Amico Risk category (n; %) | Low | 835 (44.7) | 818 (44.8) | 17 (42.5) | 0.564 | |
| Intermediate | 806 (43.1) | 790 (43.3) | 16 (40.0) | |||
| High | 225 (12) | 218 (11.9) | 7 (17.5) | |||
| Unknown | 2 (0.1) | 2 (0.1) | 0 (0) | |||
| CCI score (median; IQR) | 3 (2-3) | 3 (2-3) | 4 (3-4) | <0.001 | ||
| Estimated surgical blood loss (median, IQR) (mL) | 200 (125-375) | 200 (130-393.8) | 200 (100-337.5) | 0.313 | ||
| Length of stay (median, IQR) (days) | 1 (1-2) | 1 (1-2) | 1 (1-2) | 0.362 | ||
| Gleason score (n; %) | Diagnostic biopsy | ≤6 | 912 (49.1) | 896 (49.1) | 16 (48.5) | 0.391 |
| 7 | 770 (41.4) | 754 (41.3) | 16 (48.5) | |||
| ≥8 | 176 (1) | 175 (9.6) | 1 (3) | |||
| Pathology biopsy | ≤6 | 483 (25.9) | 473 (26) | 10 (25) | 0.797 | |
| 7 | 1235 (66.4) | 1207 (66.4) | 28 (70) | |||
| ≥8 | 141 (7.6) | 139 (7.6) | 2(5) | |||
| Tumor stage (median, range) | 5 (5-5) | 5 (5-5) | 0.213 | |||
Retinal and CNS-related comorbidities of patients who underwent RALP.
| Preexisting comorbidity | Number of patients with comorbidity (% total) | p (control vs. study group) | ||
|---|---|---|---|---|
| All patients | Control Group | Study Group | ||
| CNS | 24 (1.3) | - | 24 | - |
| Retinal | 15 (0.8) | - | 15 | - |
| CNS+retinal | 1 (0.1) | - | 1 | - |
| CAD | 0 (0) | 0 (0) | 0 (0) | - |
| CHF | 1 (0.1) | 0 (0) | 1 (2.5) | 0.021 |
| COPD/Pulmonary | 128 (6.9) | 124 (6.8) | 4 (10.0) | 0.349 |
| Diabetes | 149 (8) | 146 (8.0) | 3 (7.5) | 1.0 |
| Connective Tissue | 1 (0.1) | 1 (0.1) | 0 (0) | 1.0 |
| Peptic Ulcer Disease | 119 (6.4) | 116 (6.3) | 3 (7.5) | 0.739 |
| Renal Insufficiency | 51 (2.7) | 48 (2.6) | 3 (7.5) | 0.093 |
| Cerebrovascular | 26 (1.4) | 2 (0.1) | 24 (60.0) | <0.001 |
| Peripheral Vascular | 100 (5.4) | 96 (5.3) | 4 (10.0) | 0.163 |
| Lymphoma | 0 (0) | 0 (0) | 0 (0) | - |
| MI | 90 (4.8) | 90 (4.9) | 0 (0) | 0.259 |
| Liver | 1 (0.1) | 1 (0.1) | 0 (0) | 1.0 |
| Any | 544 (29.1) | 516 (28.2) | 28 (70.0) | <0.001 |
Incidence of complications in patients following RALP surgery.
| Complication | Number of patients with complication (% total) | p (control vs. study group) | ||
|---|---|---|---|---|
| All patients | Control Group | Study Group | ||
| CNS | 0 (0) | 0 (0) | 0 (0) | - |
| Retinal | 0 (0) | 0 (0) | 0 (0) | - |
| Cardiac | 3 (0.2) | 3 (0.2) | 0 (0) | 1.0 |
| Respiratory | 5 (0.3) | 5 (0.3) | 0 (0) | 1.0 |
| Genito-urinary | 121 (6.5) | 118 (6.5) | 3 (7.5) | 0.741 |
| Gastrointestinal | 48 (2.6) | 47 (2.6) | 1 (2.5) | 1.0 |
| Infection | 44 (2.4) | 43 (2.4) | 1 (2.5) | 0.619 |
| Vascular | 44 (2.4) | 42 (2.3) | 2 (5) | 0.242 |
| Nausea | 0 (0) | 0 (0) | 0 (0) | - |
| Misc. Medical | 13 (0.7) | 12 (0.7) | 1 (2.5) | 0.246 |
| Misc. Surgical | 46 (2.5) | 46 (2.5) | 0 (0) | 0.623 |
| Other | 0 (0) | 0 (0) | 0 (0) | - |
| Death | 0 (0) | 0 (0) | 0 (0) | - |
| ANY | 268 (14.3) | 261 (14.3) | 7 (17.5) | 0.50 |
Clavien grading of complications in control and study groups.
| Clavien grading | Number of patients (%) | P (control vs. study group) | |
|---|---|---|---|
| Control group | Study group | ||
| 1 | 70 (3.8) | 0 (0) | 0.4 |
| 2 | 92 (5) | 4 (10) | 0.146 |
| 3a | 32 (1.8) | 0 (0) | 1.0 |
| 3b | 108 (5.9) | 3 (7.5) | 0.729 |
| 4 | 12 (0.7) | 1 (2.5) | 0.246 |
| 5 | 0 (0) | 0 (0) | - |
| Minor complications (Clavien 1-2) | 156 (8.5) | 4 (10.0) | 0.772 |
| Major Complications (Clavien 3-5) | 146 (8.0) | 4 (10) | 0.557 |